THRD appoints new CFO, provides THB335 update; IND filing on track for H1 2024

Third Harmonic Bio, Inc.

Christopher M. Murphy appointed CFO and Business Officer effective Jan 4, 2024; base salary $495K, annual bonus up to 40%, option for 410,000 shares.
Murphy previously held leadership roles at Horizon Therapeutics, including Group VP Commercial Operations and Business Development.
THB335 IND-enabling toxicology studies nearing completion; pre-IND FDA interaction complete.
Company on track to file U.S. IND and initiate Phase 1 SAD/14-day MAD study in first half of 2024.
Cash and cash equivalents $273.9M as of Sept 30, 2023; strong financial position.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher M. Murphy

Chief Financial and Business Officer

Third Harmonic Bio, Inc.

Effective: 2024-01-04
Filed: January 4, 2024, 6:59 PM ET

On January 4, 2024, Third Harmonic Bio, Inc. (the “ Company ”), announced the appointment of Christopher M. Murphy, age 40, as the Company’s Chief Financial and Business Officer and principal financial officer, effective as of January 4, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher M. Murphy was appointed as Chief Financial and Business Officer at Third Harmonic Bio, Inc..

Action: appointed
Role: Chief Financial and Business Officer

Exact text from the filing

On January 4, 2024, Third Harmonic Bio, Inc. (the “ Company ”), announced the appointment of Christopher M. Murphy, age 40, as the Company’s Chief Financial and Business Officer and principal financial officer, effective as of January 4, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-001929

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.